The BC Bud Co. Applauds DEA Action, Prepares for North American Opportunities and Provides Corporate Update
The BC Bud (CSE: BCBC) (OTCQB: BCBCF) applauds DEA action to reschedule cannabis, preparing for North American opportunities. The US Department of Justice may reclassify cannabis as a Schedule III controlled substance, aligning it with prescription medications. The company is exploring M&A opportunities, focusing on direct delivery initiatives, and anticipating a prosperous 2024 in the cannabis market.
The BC Bud Co. applauds the DEA action to reschedule cannabis, recognizing the medicinal benefits and potential growth opportunities in the industry.
The company's focus on responsibility, maturity, and longevity, supported by financial prudence and industry expertise, positions it well for sustainable growth.
The BC Bud Co. is actively pursuing M&A prospects in North America and beyond, leveraging its experience and seeking strategic partnerships for future growth.
The company's initiative on direct delivery services enhances accessibility and transparency of its premium cannabis products, strengthening customer-centric services.
As Canada's cannabis market matures and bottoms out, The BC Bud Co. is strategically positioned for a prosperous and transformative 2024, welcoming stakeholders to join in its journey.
- None.
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - The BC Bud Corporation (CSE: BCBC) (OTCQB: BCBCF) ("The BC Bud Co" or the "Company"), a house of high-quality cannabis brands based out of British Columbia, Canada, applauds the DEA and US Federal movement towards rescheduling cannabis.
The Biden administration is poised to reclassify cannabis as a substance of lower risk, marking a historic and timely shift that recognizes the medicinal benefits of a long-criminalized and unfairly stigmatized drug. This move carries significant implications for cannabis-related research and the industry as a whole.
The US Department of Justice is anticipated to suggest the rescheduling of cannabis as a Schedule III controlled substance. This classification aligns it with prescription medications like ketamine and Tylenol with codeine.
"The BC Bud Co has long awaited this historic shift and remains dedicated to evaluating opportunities across North America and soon globally to introduce our brands to evolving consumer markets," stated CEO Brayden Sutton. "We are confident in our positioning for growth, despite the challenges present in the cannabis sector. Preparation for this change has involved ongoing discussions with key US contacts over an extended period. With conditions becoming increasingly favorable for commerce in the cannabis space, we are committed to advancing these discussions further."
Focused on Responsibility, Maturity and Longevity
The BC Bud Co. stands out as a responsible yet street-smart participant in the cannabis market. Backed by a history of financial prudence and deep-rooted experience in the industry, the company has primarily relied on funding from its founders and management, laying a robust foundation for sustainable growth with ready access to capital as needed. By consciously opting to remain asset-light, the company prioritizes its products and the consumer experience over infrastructure and human capital.
Exploring M&A Opportunities
Primed for strategic growth in North America and beyond, The BC Bud Co. is actively pursuing promising Merger and Acquisition prospects, though at this time no specific transactions have progressed beyond initial negotiations. Drawing upon its wealth of industry expertise, the company is ready to forge potential partnerships in the United States and abroad. Moreover, The BC Bud Co. is actively scouting for US-based advisors to access top-tier, value-enhancing opportunities.
Direct Delivery Initiatives
Aligned with its dedication to customer-centric services, The BC Bud Co. is ramping up its focus on direct delivery services to bolster the accessibility and transparency of its premium cannabis products with new BC-based partners.
Anticipating a Prosperous 2024
As Canada enters its sixth year of cannabis legalization, The BC Bud Co. looks ahead with optimism, particularly as the sector navigates a bottoming-out phase. Positioned strategically, the company is poised to seize emerging opportunities for a prosperous and transformative 2024. The BC Bud Co. welcomes stakeholders, partners, and the public to join in its journey toward ongoing success. For further details, please visit www.TheBCBC.com or reach out via email at info@thebcbc.com.
About The BC Bud Co.
The BC Bud Co. is a publicly traded Canadian cannabis company headquartered in British Columbia. Renowned for its responsibility, maturity, and unwavering commitment to quality, the company is steadfastly dedicated to overcoming the challenges inherent in the cannabis sector while striving for sustained growth.
Investor Relations
Phone: 1-(778)-656-0377
Email: info@thebcbc.com
Web: www.thebcbc.com
Disclaimer
Forward-Looking Statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties, and other factors.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions, including the effects of COVID-19. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207572
